CARRY WEALTH (00643) clarifies that Hu Dongmei has not become and is not a director of the company.
CARRY WEALTH (00643) issued an announcement that the board of directors of the company wishes to clarify that the appointment of Hu Dongmei (Ms. Hu) as an executive director of the company as stated in the announcement dated November 16, 2026 and titled "Appointment of Executive Director" (the Appointment Announcement) was not approved by the board of directors and therefore did not take effect.
CARRY WEALTH (00643) announces that the board of directors of the Company wishes to clarify that the appointment of Hu Dongmei (Ms. Hu) as an executive director of the Company as stated in the announcement dated 16 November 2026 titled "Appointment of Executive Director" (the Appointment Announcement) was not approved by the Board and therefore did not take effect.
Accordingly, Ms. Hu has not become and is not a director of the Company. Shareholders and potential investors should disregard the statements or implications in the Appointment Announcement and the List of Directors that Ms. Hu has been appointed as a director of the Company or that such appointment has taken effect from 16 November 2026.
The statement in the Appointment Announcement that Ms. Hu "has been appointed as an executive director with effect from 16 November 2026", and the listing of Ms. Hu as an executive director among the members of the Board set out in the List of Directors and the Appointment Announcement, are inaccurate. This clarification is made pursuant to Rule 2.13 of the Listing Rules.
Related Articles

LEADS BIOLABS-B (09887): Trustee purchases 220,700 H shares under the H-share award scheme

Deshi Technology (02526) is about to globally debut the upgraded iMedLoop, connecting the "personal + clinical + research" three entry points for the first time.

BOAN BIOTECH (06955): BA1104 (nivolumab) China Phase III clinical trial completed and met primary endpoint
LEADS BIOLABS-B (09887): Trustee purchases 220,700 H shares under the H-share award scheme

Deshi Technology (02526) is about to globally debut the upgraded iMedLoop, connecting the "personal + clinical + research" three entry points for the first time.

BOAN BIOTECH (06955): BA1104 (nivolumab) China Phase III clinical trial completed and met primary endpoint






